tiprankstipranks
Trending News
More News >
MannKind Corporation (MNKD)
:MNKD
US Market

MannKind (MNKD) Earnings Dates, Call Summary & Reports

Compare
1,804 Followers

Earnings Data

Report Date
Aug 06, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
0.05
Last Year’s EPS
-0.01
Same Quarter Last Year
Based on 6 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 08, 2025
|
% Change Since: -9.69%
|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlights strong growth in the endocrine business, successful partnerships, and promising developments in the pipeline, particularly with the Tyvaso DPI and Afrezza. However, there are challenges with the V-Go product and slower-than-expected growth in Afrezza's net revenue. Overall, the positive aspects outweigh the negatives, indicating a generally optimistic outlook.
Company Guidance
During the MannKind Corporation's first quarter 2025 earnings call, CEO Michael Castagna and CFO Chris Prentiss provided detailed guidance on the company’s performance and strategic direction. Key highlights included a 20% growth in their endocrine business on new prescriptions (NRx) and a 14% increase on total prescriptions (TRx). The Tyvaso collaboration with United Therapeutics yielded a Q1 royalty revenue of $30 million and manufacturing revenue of $29 million. MannKind reported a non-GAAP income of $22 million, marking a 43% increase over the prior year. The company’s new and recurring prescription growth showed a 26% year-over-year increase among their top 50 prescribers. Additionally, MannKind is advancing its pipeline, with promising developments in inhaled clofazimine (MNKD-101) and nintedanib (MNKD-201), as well as plans for a pediatric expansion of Afrezza in mid-2025. The company ended the quarter with net revenues growing by 18%, supported by the strong performance of Tyvaso DPI royalties, which increased by 32% over the previous year. MannKind reported a net income of $13 million or $0.04 per share, a 24% increase from the first quarter of 2024.
Endocrine Business Growth
The endocrine business grew 20% on NRxs and 14% on TRxs, indicating strong performance and demand.
Strong Partnership with United Therapeutics
The collaboration with United Therapeutics resulted in Q1 royalty revenue of $30 million and manufacturing revenue of $29 million.
Non-GAAP Income Growth
Reported non-GAAP income of $22 million, showing a 43% growth over the previous year.
Afrezza Demand and Expansion
Successful interactions and increased demand at the ATTD conference, with a focus on global expansion and pediatric opportunities.
Tyvaso DPI Revenue and Market Potential
Received $29 million in manufacturing revenue from Tyvaso DPI, with the market expected to exceed $1 billion by the end of the decade.

MannKind (MNKD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

MNKD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 2025
2025 (Q2)
0.05 / -
-0.01
May 08, 2025
2025 (Q1)
0.04 / 0.04
0.040.00% (0.00)
Feb 26, 2025
2024 (Q4)
0.04 / 0.03
0
Nov 07, 2024
2024 (Q3)
0.03 / 0.04
0.01300.00% (+0.03)
Aug 07, 2024
2024 (Q2)
<0.01 / -0.01
-0.0250.00% (+0.01)
May 08, 2024
2024 (Q1)
0.03 / 0.04
-0.04200.00% (+0.08)
Feb 27, 2024
2023 (Q4)
<0.01 / 0.00
-0.07
Nov 07, 2023
2023 (Q3)
-0.02 / 0.01
-0.06116.67% (+0.07)
Aug 07, 2023
2023 (Q2)
-0.04 / -0.02
-0.1181.82% (+0.09)
May 09, 2023
2023 (Q1)
-0.05 / -0.04
-0.160.00% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

MNKD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 08, 2025
$4.85$4.63-4.54%
Feb 26, 2025
$5.47$5.23-4.39%
Nov 07, 2024
$7.39$7.34-0.68%
Aug 07, 2024
$5.27$5.01-4.93%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does MannKind Corporation (MNKD) report earnings?
MannKind Corporation (MNKD) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
    What is MannKind Corporation (MNKD) earnings time?
    MannKind Corporation (MNKD) earnings time is at Aug 06, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is MNKD EPS forecast?
          MNKD EPS forecast for the fiscal quarter 2025 (Q2) is 0.05.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis